Progression-free survival of two cases of high-risk neuroblastoma with refractory/relapsed disease following surgery alone

Elizabeth Sokol, Paul Haut, Yasmin Gosiengfiao, Kate Feinstein, Peter Pytel, Susan L. Cohn

Research output: Contribution to journalArticle

Abstract

Outcome for the vast majority of high-risk neuroblastoma patients with refractory or relapsed disease is dismal. We report two high-risk patients who remain progression-free for more than 113 and 18 months following the diagnosis of refractory/relapsed disease who were treated with surgery alone. Complete resolution of a refractory thoracic mass and relapsed liver nodules was observed in one patient. The refractory/relapsed disease in the second patient has remained stable. In both cases, the tumor showed histologic evidence of neuroblastoma maturation. These cases demonstrate that refractory/relapsed neuroblastoma is clinically heterogeneous and highlight the need for better biomarkers to optimize patient care.

Original languageEnglish
Pages (from-to)512-514
Number of pages3
JournalPediatric Blood and Cancer
Volume60
Issue number3
DOIs
StatePublished - Mar 2013

Fingerprint

Neuroblastoma
Disease-Free Survival
Patient Care
Thorax
Biomarkers
Liver
Neoplasms

Keywords

  • Neuroblastoma
  • Pathology
  • Refractory neuroblastoma
  • Relapsed neuroblastoma

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Progression-free survival of two cases of high-risk neuroblastoma with refractory/relapsed disease following surgery alone. / Sokol, Elizabeth; Haut, Paul; Gosiengfiao, Yasmin; Feinstein, Kate; Pytel, Peter; Cohn, Susan L.

In: Pediatric Blood and Cancer, Vol. 60, No. 3, 03.2013, p. 512-514.

Research output: Contribution to journalArticle

Sokol, Elizabeth ; Haut, Paul ; Gosiengfiao, Yasmin ; Feinstein, Kate ; Pytel, Peter ; Cohn, Susan L. / Progression-free survival of two cases of high-risk neuroblastoma with refractory/relapsed disease following surgery alone. In: Pediatric Blood and Cancer. 2013 ; Vol. 60, No. 3. pp. 512-514.
@article{90b1a4d55ce043d6b84c48ef23867d83,
title = "Progression-free survival of two cases of high-risk neuroblastoma with refractory/relapsed disease following surgery alone",
abstract = "Outcome for the vast majority of high-risk neuroblastoma patients with refractory or relapsed disease is dismal. We report two high-risk patients who remain progression-free for more than 113 and 18 months following the diagnosis of refractory/relapsed disease who were treated with surgery alone. Complete resolution of a refractory thoracic mass and relapsed liver nodules was observed in one patient. The refractory/relapsed disease in the second patient has remained stable. In both cases, the tumor showed histologic evidence of neuroblastoma maturation. These cases demonstrate that refractory/relapsed neuroblastoma is clinically heterogeneous and highlight the need for better biomarkers to optimize patient care.",
keywords = "Neuroblastoma, Pathology, Refractory neuroblastoma, Relapsed neuroblastoma",
author = "Elizabeth Sokol and Paul Haut and Yasmin Gosiengfiao and Kate Feinstein and Peter Pytel and Cohn, {Susan L.}",
year = "2013",
month = "3",
doi = "10.1002/pbc.24385",
language = "English",
volume = "60",
pages = "512--514",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Progression-free survival of two cases of high-risk neuroblastoma with refractory/relapsed disease following surgery alone

AU - Sokol, Elizabeth

AU - Haut, Paul

AU - Gosiengfiao, Yasmin

AU - Feinstein, Kate

AU - Pytel, Peter

AU - Cohn, Susan L.

PY - 2013/3

Y1 - 2013/3

N2 - Outcome for the vast majority of high-risk neuroblastoma patients with refractory or relapsed disease is dismal. We report two high-risk patients who remain progression-free for more than 113 and 18 months following the diagnosis of refractory/relapsed disease who were treated with surgery alone. Complete resolution of a refractory thoracic mass and relapsed liver nodules was observed in one patient. The refractory/relapsed disease in the second patient has remained stable. In both cases, the tumor showed histologic evidence of neuroblastoma maturation. These cases demonstrate that refractory/relapsed neuroblastoma is clinically heterogeneous and highlight the need for better biomarkers to optimize patient care.

AB - Outcome for the vast majority of high-risk neuroblastoma patients with refractory or relapsed disease is dismal. We report two high-risk patients who remain progression-free for more than 113 and 18 months following the diagnosis of refractory/relapsed disease who were treated with surgery alone. Complete resolution of a refractory thoracic mass and relapsed liver nodules was observed in one patient. The refractory/relapsed disease in the second patient has remained stable. In both cases, the tumor showed histologic evidence of neuroblastoma maturation. These cases demonstrate that refractory/relapsed neuroblastoma is clinically heterogeneous and highlight the need for better biomarkers to optimize patient care.

KW - Neuroblastoma

KW - Pathology

KW - Refractory neuroblastoma

KW - Relapsed neuroblastoma

UR - http://www.scopus.com/inward/record.url?scp=84872444768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872444768&partnerID=8YFLogxK

U2 - 10.1002/pbc.24385

DO - 10.1002/pbc.24385

M3 - Article

C2 - 23129137

AN - SCOPUS:84872444768

VL - 60

SP - 512

EP - 514

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 3

ER -